Project Grant K08CA297137
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $278K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $172,889 on January 12, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and optimize chimeric antigen receptor (CAR) T-cell therapies for acute myeloid leukemia (AML). The funded research applies structure-guided protein evolution to improve natural ligand-based CAR-T therapies targeting CD70 in AML. The project uses computational deep learning algorithms and high-throughput...
- The National Cancer Institute awarded The Leland Stanford Junior University $137,266 on July 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop comprehensive profiling methods for T-cell lymphomas and personalized therapeutic interventions. The project encompasses three research aims. Aim 1 develops disease monitoring and clonal evolution assessment in T-cell lymphoma by integrating targeted sequencing of cell-free DNA to detect circulating tumor DNA, viral genomes,...
- The National Cancer Institute awarded The Leland Stanford Junior University $100,228 on February 13, 2027, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical training and research in cancer immunotherapy. Performance extends through September 21, 2029, at Stanford's Palo Alto, California location. The award funds research on co-engineered CAR T cells and CAR macrophages for glioblastoma treatment. The project applies a synthetic cytokine receptor (SCR) platform to...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $683,270 on August 12, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the mechanisms of BCMA CAR-T–mediated enteritis in multiple myeloma patients. The research employs single-cell and spatial multi-omics to analyze tissue and blood samples from BCMA CAR-T enteritis patients and controls, including patients with immune checkpoint inhibitor-induced enterocolitis and...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $287,320 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support clinical research training and career development in cancer research. The award is a K08 Project Grant. The research addresses predictive models and biomarker discovery for immune checkpoint inhibitor treatment outcomes in hepatocellular carcinoma patients. Specifically, the work will refine and...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $263,656 on August 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research into novel mechanisms of acute myeloid leukemia (AML) resistance to chimeric antigen receptor T cell (CAR-T) therapy. The research aims to develop a detailed understanding of how altered STAT5 levels dictate poor outcomes for AML CAR-T therapies and to identify a combination therapy that selectively blocks AML...
- The National Cancer Institute, within the Department of Health and Human Services, awarded $442,146 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a first-in-class clinical trial of natural killer cell therapy engineered to target intracellular antigens in acute myeloid leukemia and high-risk myelodysplastic syndromes. The funded work develops and tests cord blood-derived, off-the-shelf NK cells...
- The National Cancer Institute awarded the University of California, San Diego $304,168 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on disrupting the proteostasis network in acute myeloid leukemia. The funded research tests the hypothesis that disrupting proteostasis can impair AML by inhibiting protein degradation through combined proteasome and autophagy inhibitors and determining whether PKR, an EIF2A kinase, mediates integrated stress...
- The National Institutes of Health National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $146,299 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) for a K99 postdoctoral career development grant supporting research into cancer cell surface remodeling and engineered immunotherapy. The funded research investigates how dynamic cell surface changes during cancer progression shape tumor-immune interactions and fibrosis, with particular focus...
- The National Cancer Institute awarded the University of Southern California $137,459 on June 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support a K01 career development award for research on spatially controlled priming of CAR T cells in solid tumors via focused ultrasound. The award funds a structured early-career research and training program to develop a focused ultrasound-based gene control system that enables spatially confined T cell priming within the tumor...